Galectin Therapeutics Inc (GALT)
3.14
+0.08
(+2.61%)
USD |
NASDAQ |
May 16, 16:00
3.15
+0.01
(+0.32%)
After-Hours: 20:00
Galectin Therapeutics Cash from Financing (Quarterly): 10.00M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.00M |
| September 30, 2023 | 10.03M |
| June 30, 2023 | 10.00M |
| March 31, 2023 | 10.00M |
| December 31, 2022 | 10.00M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 9.999M |
| September 30, 2021 | 10.00M |
| June 30, 2021 | 16.82M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.044M |
| March 31, 2020 | 0.219M |
| December 31, 2019 | 0.902M |
| September 30, 2019 | -0.231M |
| June 30, 2019 | 47.40M |
| March 31, 2019 | 2.003M |
| December 31, 2018 | 0.124M |
| September 30, 2018 | 1.216M |
| June 30, 2018 | 9.588M |
| March 31, 2018 | 4.451M |
| December 31, 2017 | -0.001M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.954M |
| June 30, 2017 | 0.485M |
| March 31, 2017 | 2.145M |
| December 31, 2016 | 4.168M |
| September 30, 2016 | 1.50M |
| June 30, 2016 | 0.257M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 9.128M |
| September 30, 2015 | 0.041M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 4.532M |
| December 31, 2014 | 1.04M |
| September 30, 2014 | 0.06M |
| June 30, 2014 | 0.241M |
| March 31, 2014 | 30.12M |
| December 31, 2013 | 2.42M |
| September 30, 2013 | 6.099M |
| June 30, 2013 | 0.013M |
| March 31, 2013 | 0.077M |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 10.40M |
| December 31, 2011 | 0.00 |
| September 30, 2011 | 1.216M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.231M
Minimum
Sep 2019
47.40M
Maximum
Jun 2019
7.115M
Average
0.902M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 573.71M |
| Viking Therapeutics Inc | 606.04M |
| 89bio Inc | 21.03M |
| Terns Pharmaceuticals Inc | 0.00 |
| Enanta Pharmaceuticals Inc | -6.414M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.702M |
| Free Cash Flow | -32.96M |
| Free Cash Flow Per Share (Quarterly) | -0.076 |
| Free Cash Flow Yield | -17.45% |